Femasys Inc. Common Stock (FEMY)

Price$0.38

Value ScoreD

Growth ScoreA

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-67.57%

Price vs S&P 500 (4W)-4.19%

VGM Score41.45

Market Capitalization$23.37M

All Metrics

Book Value / Share (Quarterly)$0.12

P/TBV (Annual)5.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)23.75%

Cash Flow / Share (Quarterly)$-0.31

Price vs S&P 500 (YTD)-43.77%

Gross Margin (TTM)61.56%

Net Profit Margin (TTM)-500.01%

EPS (TTM)$-0.31

10-Day Avg Trading Volume3.59M

EPS Excl Extra (TTM)$-0.31

Revenue Growth (5Y)17.13%

EPS (Annual)$-0.47

ROI (Annual)-205.87%

Gross Margin (Annual)61.96%

Net Profit Margin (5Y Avg)-975.33%

Cash / Share (Quarterly)$0.09

Revenue Growth QoQ (YoY)24.51%

ROA (Last FY)-89.88%

Revenue Growth TTM (YoY)39.88%

EBITD / Share (TTM)$-0.30

ROE (5Y Avg)-262.99%

Operating Margin (TTM)-687.93%

Cash Flow / Share (Annual)$-0.32

P/B Ratio3.21x

P/B Ratio (Quarterly)3.48x

Net Income / Employee (Annual)$-365,300

EV / Revenue (TTM)8.97x

Net Interest Coverage (TTM)-9.41x

ROA (TTM)-70.65%

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)4.53x

Quick Ratio (Quarterly)1.98x

3-Month Avg Trading Volume0.87M

52-Week Price Return-62.06%

Revenue / Employee (TTM)$46,600

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)10.19x

Asset Turnover (Annual)0.11x

52-Week High$1.11

Operating Margin (5Y Avg)-975.52%

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)83.85%

26-Week Price Return-51.64%

Quick Ratio (Annual)2.95x

13-Week Price Return-30.68%

Total Debt / Equity (Annual)0.54x

Current Ratio (Quarterly)3.91x

Enterprise Value$21.32M

Revenue / Share Growth (5Y)-8.08%

Asset Turnover (TTM)0.14x

Revenue / Employee (Annual)$45,000

Inventory Turnover (Annual)0.20x

Pretax Margin (Annual)-812.21%

Cash / Share (Annual)$0.16

3-Month Return Std Dev101.64%

Gross Margin (5Y Avg)64.90%

Net Income / Employee (TTM)$-233,000

ROE (Last FY)-317.38%

Net Interest Coverage (Annual)-7.05x

EPS Basic Excl Extra (Annual)$-0.47

Receivables Turnover (TTM)11.71x

Total Debt / Equity (Quarterly)0.46x

EPS Incl Extra (TTM)$-0.31

Receivables Turnover (Annual)4.15x

ROI (TTM)-123.16%

P/S Ratio (TTM)9.83x

Pretax Margin (5Y Avg)-974.95%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$0.10

Price vs S&P 500 (52W)-90.26%

Year-to-Date Return-32.84%

5-Day Price Return-11.64%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)-77.24%

Net Profit Margin (Annual)-812.27%

Month-to-Date Return5.97%

Cash Flow / Share (TTM)$-0.94

EBITD / Share (Annual)$-0.44

Operating Margin (Annual)-766.96%

LT Debt / Equity (Annual)0.54x

ROI (5Y Avg)-122.54%

LT Debt / Equity (Quarterly)0.46x

EPS Basic Excl Extra (TTM)$-0.31

P/TBV (Quarterly)3.54x

P/B Ratio (Annual)5.84x

Inventory Turnover (TTM)0.18x

Pretax Margin (TTM)-499.78%

Book Value / Share (Annual)$0.10

Price vs S&P 500 (13W)-40.43%

Beta-2.30x

Revenue / Share (TTM)$0.03

ROE (TTM)-247.31%

52-Week Low$0.31

vGradeD

gGradeA

mGradeF

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.06est. -0.09

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

4.10

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
FEMYFemasys Inc. Common Stock	D	A	F	$0.38
SYKStryker Corporation	C	C	D	$299.46
MMM3M Company	C	F	C	$150.93
BSXBoston Scientific Corp.	C	B	F	$47.98
MDLNMedline Inc. Class A common stock	C	D	D	$35.75
BDXBecton, Dickinson and Co.	B	C	C	$145.33
DXCMDexCom, Inc.	C	B	C	$74.87
RMDResMed Inc.	B	B	D	$186.44
WSTWest Pharmaceutical Services, Inc.	D	C	B	$316.30
SOLVSolventum Corporation	C	D	C	$75.84
PENPenumbra, Inc.	F	C	C	$318.95

About

Femasys develops minimally invasive medical devices for women's healthcare, offering office-based solutions for infertility treatment, contraception, and diagnostic procedures. Its product portfolio includes FemaSeed for intratubal insemination, FemVue for fallopian tube assessment, FemBloc for permanent contraception (in development), FemCerv for cervical cancer diagnosis, and FemCath and FemChec. The company generates revenue primarily from the United States market with additional international sales.